153 search results for: type 2 inflammation

EADV 2025
Congress
17
September
2025
Congress
EADV 2025 Congress

ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.

On-Treatment Clinical Remission in Asthma Patients Case Tool
Pulmonology
On-Treatment Clinical Remission in Asthma Patients Case Tool
interactivity

Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

View more
Expert Interview with Dr Jason Hawkes
Dermatology
Expert Interview with Dr Jason Hawkes
expert video

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.

View more
ESPD <b>2</b>0<b>2</b>4 | Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
On Demand
ESPD 2024 | Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Pulmonology
ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Podcast

Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

View more
European Academy of Dermatology and Venereology (EADV) <b>2</b>0<b>2</b>3 | Berlin
Congress
11
October
2023
Congress
European Academy of Dermatology and Venereology (EADV) 2023 | Berlin

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

ADVENT at EADV 2024
Congress
25
September
2024
Congress
ADVENT at EADV 2024

Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.

 

ADVENT Forum 2025 Event Page
Awareness Day
4
April
2025
Awareness Day
ADVENT Forum 2025 Event Page

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

Skin Barrier Dysfunction in AD
Dermatology
Skin Barrier Dysfunction in AD
expert video

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

View more
Dysbiosis, Skin Infections, and Itch
Dermatology
Dysbiosis, Skin Infections, and Itch
expert video

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.

View more
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis
On Demand
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.